



FORT WAYNE  
MEDICAL ONCOLOGY  
AND HEMATOLOGY

HOPE THROUGH COMPASSION & INNOVATION

NORTH OFFICE  
11143 Parkview Plaza Drive  
Suite 100  
Fort Wayne, Indiana 46845  
(260) 484-8830

August 22, 2017

SOUTH OFFICE  
7910 West Jefferson Boulevard  
Suite 108  
Fort Wayne, Indiana 46804  
(260) 436-0800

www.fwmoh.com



UNITED STATES NUCLEAR REGULATORY COMMISSION

Region III, Materials Licensing Section

2443 Warrenville Road

Suite 210

Lisle, IL 60532-4352

Re: License Number 13-32722-01, Fort Wayne Medical Oncology and Hematology, Inc.

Please add Dr. Andre Byard Stovall, M.D., Andrew J. Norton, M.D., Shawn Johnson, M.D., and James A. Arata, M.D. as Authorized Users for 10 CFR 35.100 and 35.200. All physicians are listed as Authorized Users on NRC License 13-01535-01 which is enclosed for your review.

Thank you for your cooperation with this matter. If you have any questions or require additional information please contact our physics consultant, Michelle Kritzman, at (734) 662-3197 or by email at mkritzman@mpcphysics.com.

Sincerely,

Amy L. Lowden

COO/CFO

RECEIVED AUG 25 2017

Farrukh M. Adhami, M.D.  
Lakshmi Aggarwal, M.D.  
Sunil Babu, M.D.  
Matthew L. Carr, M.D.

Shalini Chitneni, M.D.  
Michael Epstein, M.D.  
Gary R. Gize, M.D.  
Ryan Gonzales, M.D.

Praveen Kollipara, M.D.  
Yasolatha Nalamolu, M.D.  
Sreenivasa R. Nattam, M.D.  
Dolly Quispe, M.D.

Steven N. Rhinehart, M.D.  
Ahad Sadiq, M.D.  
Charles J. Whalen, M.D.  
David M. Zimmerman, M.D.

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 of 6 PAGES  
Amendment No. 75**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with letter/application dated <b>May 12, 2015,</b>	
1. QHG of Indiana, Inc.		3. License No. 13-01535-01 is renewed in its entirety to read as follows:	
2. 7950 West Jefferson Blvd. Fort Wayne, Indiana 46804-1677		4. Expiration Date: <b>August 31, 2025</b>	
		5. Docket No. 030-01594 Reference No.	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed	
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed	
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie	
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed sources (North American Scientific, Inc., Model MED 3631; Bard Model STM1251; Best Industries, Model 2301; Implant Sciences Corp., I-Plant, Model 3500; IsoAid, LLC, Model IAI- 125A; and Mills Biopharmaceuticals, Inc., Models SL-125 and SH- 125)	D. 1 curie	
E. Palladium-103 permitted by 10 CFR 35.400	E. Sealed sources (North American Scientific, Inc., Model MED 3633; Best Medical International Inc., Model 2335; and Theragenics Corp. Theraseed, Model 200)	E. 1 curie	
F. Cesium-131 permitted by 10 CFR 35.400	F. Sealed sources (IsoRay Medical Inc. Model #CS-1)	F. 1 curie	

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 6 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.  
13-01535-01

Docket or Reference No.  
030-01594

Amendment No. 75

G. Any byproduct material permitted by 10 CFR 35.500

G. Sealed sources (North American Scientific, Inc., Models MED 3601 and Du Pont Merck Pharmaceutical Company NES-8412)

G. 300 millicuries per source and 1200 millicuries total

H. Any byproduct material permitted by 10 CFR 31.11

H. Prepackaged kits

H. 1 millicurie

I. Yttrium-90 permitted by 10 CFR 35.1000

I. Sealed sources as SIR-Spheres (AEA Technology QSA, Inc.)

I. 2 curies

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. through F. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

G. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

H. *in vitro* studies.

I. Medical use permitted by 10 CFR 35.1000 in a Sirtex Medical Limited brachytherapy afterloader delivery system.

CONDITIONS

10. A. Licensed material may be used or stored only at the licensee's facilities located at 7950 West Jefferson Boulevard, Fort Wayne, Indiana.

B. Licensed material listed in Subitems 6.A. and 6.B. may be used and stored at 7916 West Jefferson Blvd, Fort Wayne, Indiana.

11. The Radiation Safety Officer for this license is Randall J. Phillips, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 6 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.

13-01535-01

Docket or Reference No.

030-01594

Amendment No. 75

**B. The following individuals are authorized users for medical use as indicated:**

<u>Authorized User</u>	<u>Material and Use</u>
Brett A. Hagedorn, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
John Rock, M.D.	10 CFR 35.100, 35.200, and 31.11.
Rik Stephens, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500, and 31.11.
James C. Wehrenberg, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
David B. Janizek, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500, and 31.11.
Christine Anne Tremper, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities equal to or less than 33 millicuries), and 35.500.
Randall J. Phillips, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500, 31.11, 35.1000 (limited to yttrium-90 SIR-spheres delivery system).
John Pasalich, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Stephen R. Phillip, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Marc Thomas, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Michael E. Parker, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Pamela Lee Strange, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Joseph R. Decamp, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to oral administration of sodium iodide I-131 in quantities equal to or less than 33 millicuries), and 35.500.
Frederick N. Vandeman, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries), and 35.500.
Andre Byard Stovall, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500 and 35.1000 (limited to yttrium-90 SIR-Spheres delivery system).
Christopher Michael Kowalski, M.D.	10 CFR 35.100, 35.200, and 35.500.
Richard W. Sibley, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Dakshesh S. Patel, M.D.	10 CFR 35.100, 35.200, and 35.500.
Eric V. Heatwole, M.D.	10 CFR 35.100, 35.200, and 35.500.
Shilpa Kashyap, M.D.	10 CFR 35.100, 35.200, and 35.500.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 6 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.

13-01535-01

Docket or Reference No.

030-01594

Amendment No. 75

<u>Authorized User</u>	<u>Material and Use</u>
Rao V. P. Mantravadi, M.D.	10 CFR 35.300 and 35.400.
Stephen Beyar, M.D.	10 CFR 35.300.
Shawn Johnson, M.D.	10 CFR 35.100, 35.200, 35.300.
John C. Lacunza, M.D.	10 CFR 35.100 and 35.200.
Eugene Shih, M.D.	10 CFR 35.100 and 35.200.
Peter C. Hanley, M.D.	10 CFR 35.100 and 35.200.
Scott E. Mattson, D.O.	10 CFR 35.100 and 35.200.
Revati J. Ghatnekar, M.D.	10 CFR 35.100 and 35.200.
Krishnan Ramani, M.D.	10 CFR 35.200.
Mark A. Meier, M.D.	10 CFR 35.200.
Venkata Rama Prasad Nalamolu, M.D.	10 CFR 35.200.
Sabeena Ramrakhiani, M.D.	10 CFR 35.100 and 35.200.
Thomas S. Chung, M.D.	10 CFR 35.300 and 35.400.
Jeffery J. Freeman, M.D.	10 CFR 100, 200, and 300 (limited to the oral administration of sodium iodide I-131).
Nathan D. Comsia, M.D.	10 CFR 35.400.
Richard B. Collins, D.O.	10 CFR 35.100 and 35.200.
Benjamin A. Tourkow, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Vivek Sharma, M.D.	10 CFR 35.100 and 35.200.
Mark A. Brinkman, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Andrew J. Norton, M.D.	10 CFR 35.100 and 35.200.
Mark C. Ranck, M.D.	10 CFR 35.400.
Wesley A. Russell, M.D.	10 CFR 35.400.
Indu Rekha Meesa, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131).

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 5 of 6 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.

13-01535-01

Docket or Reference No.

030-01594

Amendment No. 75

Authorized User

Edward K. Yi, M.D.

Joel Heitman, M.D.

Sanjiv G. Aggarwal, M.D.

James A. Arata, M.D.

Deepchand Bajai, M.D.

Andrew V. Barger, M.D.

Ravi No. Bathina, M.D.

Jonathan Berger, M.D.

John L. Bormann, M.D.

Daniel Branam, M.D.

Ryan Buss, M.D.

Material and Use

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

10 CFR 35.100 and 35.200.

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200, 35.300, 35.500, and 31.11.

10 CFR 35.300 and 35.400.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100 and 35.200.

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200, 35.300 and 35.500.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. The manufacturer's training for SIR-Spheres shall include operation of the delivery system, safety procedures, and clinical use of SIR-Spheres.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 6 of 6 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.  
13-01535-01

Docket or Reference No.  
030-01594

Amendment No. 76

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated May 12, 2015. (ML15146A271)
- B. Letter dated May 12, 2015. (ML15146A271)
- C. Letter dated June 18, 2015. (ML15175A296)

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date FEB 17 2016

By *Toye E. Simmons*  
Toye E. Simmons  
Materials Licensing Branch  
Region III



FORT WAYNE  
MEDICAL ONCOLOGY  
AND HEMATOLOGY

PET Department  
Fort Wayne Medical Oncology and Hematology  
7910 West Jefferson Boulevard, Suite 107, Fort Wayne, IN 46804  
Phone: (260) 436-0800 Fax: (260) 436-4269

To: NRC - MATERIAL LICENSING Fax #: 630 515 1078 Dept.: \_\_\_\_\_

From: Kelly H - FWMOH Date: \_\_\_\_\_ # of pages: \_\_\_\_\_  
(including cover)

Comments:

NRC - MATERIAL LICENSING

ADDING AUTH. USERS.

Thank you

Kelly Henline

FWMOH

(260) 436-0800 x 7930

Fax # 260 446-3654

Confidentiality Notice

The information contained in this communication and any enclosed material is privileged and confidential, is the property of the sender, and is intended only for the use of each person or entity named below. If you are not the intended recipient, be advised that any unauthorized disclosure, copying, or distribution, or use of this communication in error, please notify our Privacy Officer at (260) 969-7867 immediately so that she can arrange for the retrieval of this communication and any enclosed material at no cost to you.